Tandem Diabetes Care
TNDM
299 hedge funds and large institutions have $3.02B invested in Tandem Diabetes Care in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 104 increasing their positions, 120 reducing their positions, and 70 closing their positions.
16% more call options, than puts
Call options by funds: $24M | Put options by funds: $20.7M
2.34% more ownership
Funds ownership: 95.94% → 98.28% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 330 → 299 (-31)
13% less repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 120
17% less capital invested
Capital invested by funds: $3.63B → $3.02B (-$614M)
43% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 70
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$137M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$93.2M |
| 3 |
EC
Eminence Capital
New York
|
+$87.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$33.2M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$28.6M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$69.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$51.2M |
| 3 |
RI
RTW Investments
New York
|
-$32.9M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$26.2M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$25.4M |
TNDM Hedge Fund Activity: Q3 2022 in Review
299 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q3 2022, worth a combined $3.02B — down 17% from $3.63B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of TNDM and 40 opened new positions — a net loss of 30 holders — while 120 trimmed existing stakes and 104 added.
The largest buyer was Fidelity Investments, adding an estimated $137M. The largest seller was AllianceBernstein, cutting an estimated $69.2M.
- 299 institutional investors held Tandem Diabetes Care (TNDM) as of Q3 2022, down from 330 in Q2 2022.
- Funds reported $3.02B of Tandem Diabetes Care stock for Q3 2022, down 17% quarter-over-quarter.
- 40 funds opened new Tandem Diabetes Care positions in Q3 2022 and 70 closed out, a net change of -30 holders.
- The largest Tandem Diabetes Care buyer in Q3 2022 was Fidelity Investments, an estimated $137M added.
- The largest Tandem Diabetes Care seller in Q3 2022 was AllianceBernstein, an estimated $69.2M sold.
Based on aggregated 13F filings for Q3 2022.